Bicara Therapeutics BCAX Non-cash lease expense
Non-cash lease expense at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept bcax:OperatingLeaseRightOfUseAssetPeriodicReductionIncludingAdjustments.
The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's non-cash lease expense?
- Bicara Therapeutics (BCAX) reported non-cash lease expense of $223.75K in Q4 2025.
- How has Bicara Therapeutics's non-cash lease expense changed year-over-year?
- Bicara Therapeutics's non-cash lease expense increased by 1262.3% year-over-year, from -$19.25K to $223.75K.
- What is the long-term trend for Bicara Therapeutics's non-cash lease expense?
- Over 2 years (2023 to 2025), Bicara Therapeutics's non-cash lease expense has grown at a 215.3% compound annual growth rate (CAGR), from $90K to $895K.
- What does non-cash lease expense mean?
- This represents the non-cash expense recognized periodically to amortize the right-of-use asset associated with operating leases. It reflects the systematic allocation of the lease cost over the lease term, impacting net income without affecting immediate cash flow. Investors monitor this to distinguish between operational expenses that require cash outflows and those that are accounting adjustments.